atenolol has been researched along with Proteinuria in 20 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin." | 9.07 | Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. ( Apperloo, AJ; de Jong, PE; de Zeeuw, D; Sluiter, HE, 1991) |
| "Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest." | 9.05 | Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. ( Butters, L; Clark, DM; Low, RA; Reid, JL; Reynolds, B; Rubin, PC; Steedman, D; Sumner, DJ, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 7.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome." | 5.28 | Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990) |
| " There were no differences in the BP reached in the four therapy groups; however, proteinuria only decreased in the patients treated with trandolapril alone or in combination with verapamil." | 5.09 | Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs. ( Dall'Anese, C; García de Vinuesa, S; Gómez-Campderá, F; Luño, J; Ridao, N; Sánchez, M; Valderrábano, F, 2001) |
| "The aim of the study was to evaluate the efficacy of enalapril and atenolol in decreasing the severity of proteinuria in hypertensive patients suffering from insulin-dependent diabetes mellitus." | 5.07 | Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. ( Andriani, A; Bonfantino, MV; De Cesaris, R; Filitti, V; Ranieri, G, 1993) |
| "To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin." | 5.07 | Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. ( Apperloo, AJ; de Jong, PE; de Zeeuw, D; Sluiter, HE, 1991) |
| "Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest." | 5.05 | Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. ( Butters, L; Clark, DM; Low, RA; Reid, JL; Reynolds, B; Rubin, PC; Steedman, D; Sumner, DJ, 1983) |
| "Fifty patients with stable slight and moderate uncomplicated essential hypertension, treated by ramipril, atenolol, or isradipine, were examined." | 3.70 | [Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension]. ( Betekhtina, VA; Rakov, SS, 2000) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 3.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Proteinuria was assessed by urine sampling at the end of each treatment period." | 2.68 | Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis. ( Berger, E; Braun, N; Erley, CM; Heyne, N; Klass, M; Krämer, D; Risler, T; Wolf, S, 1996) |
| "Proteinuria was determined in the course of a three-day collection period at the end of each treatment phase." | 2.68 | [Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors]. ( Berger, ED; Braun, N; Erley, CM; Heyne, N; Klass, M; Krämer, D; Risler, T; Wolf, S, 1997) |
| "The progression of diabetic nephropathy can be positively influenced by maintaining a low blood pressure level." | 2.67 | Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. ( Berden, JH; de Nobel, E; Elving, LD; van Lier, HJ; Wetzels, JF, 1994) |
| "100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l." | 2.67 | Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. ( Chanard, J; Durand, D; el Esper, N; Fournier, A; Godin, M; Goldfarb, B; Hannedouche, T; Landais, P; Mignon, F; Suo, JM, 1994) |
| "Blood pressure and proteinuria are important determinants of progressive renal failure in patients with renal diseases." | 2.41 | [Intensive treatment of blood pressure in patients with kidney disease and proteinuria]. ( Huysmans, FT; Wetzels, JF, 2000) |
| "A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome." | 1.28 | Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 11 (55.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Aunapuu, M | 1 |
| Pechter, U | 1 |
| Arend, A | 1 |
| Suuroja, T | 1 |
| Ots, M | 1 |
| Lely, AT | 1 |
| van der Kleij, FG | 1 |
| Kistemaker, TJ | 1 |
| Apperloo, AJ | 2 |
| de Jong, PE | 2 |
| de Zeeuw, D | 2 |
| Navis, G | 1 |
| Rubin, PC | 1 |
| Butters, L | 1 |
| Clark, DM | 1 |
| Reynolds, B | 1 |
| Sumner, DJ | 1 |
| Steedman, D | 1 |
| Low, RA | 1 |
| Reid, JL | 1 |
| Gérard, J | 1 |
| Blazquez, G | 1 |
| Lardoux, H | 1 |
| Beauséjour, B | 1 |
| Faurie, C | 1 |
| Rousset, D | 1 |
| Flouvat, B | 1 |
| De Cesaris, R | 1 |
| Ranieri, G | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Bonfantino, MV | 1 |
| Elving, LD | 1 |
| Wetzels, JF | 2 |
| van Lier, HJ | 1 |
| de Nobel, E | 1 |
| Berden, JH | 1 |
| Hannedouche, T | 1 |
| Landais, P | 1 |
| Goldfarb, B | 1 |
| el Esper, N | 1 |
| Fournier, A | 1 |
| Godin, M | 1 |
| Durand, D | 1 |
| Chanard, J | 1 |
| Mignon, F | 1 |
| Suo, JM | 1 |
| Erley, CM | 2 |
| Klass, M | 2 |
| Krämer, D | 2 |
| Berger, E | 1 |
| Heyne, N | 2 |
| Braun, N | 2 |
| Wolf, S | 2 |
| Risler, T | 2 |
| Berger, ED | 1 |
| Hausberg, M | 1 |
| Barenbrock, M | 1 |
| Hohage, H | 1 |
| Müller, S | 1 |
| Heidenreich, S | 1 |
| Rahn, KH | 1 |
| Rakov, SS | 1 |
| Betekhtina, VA | 1 |
| Huysmans, FT | 1 |
| Bory, M | 1 |
| García de Vinuesa, S | 1 |
| Luño, J | 1 |
| Gómez-Campderá, F | 1 |
| Ridao, N | 1 |
| Sánchez, M | 1 |
| Dall'Anese, C | 1 |
| Valderrábano, F | 1 |
| Stornello, M | 1 |
| Valvo, EV | 1 |
| Scapellato, L | 1 |
| Sluiter, HE | 1 |
| Blake, S | 1 |
| MacDonald, D | 1 |
| Shapira, Y | 1 |
| Mor, F | 1 |
| Friedler, A | 1 |
| Wysenbeek, AJ | 1 |
| Weinberger, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for atenolol and Proteinuria
| Article | Year |
|---|---|
[Intensive treatment of blood pressure in patients with kidney disease and proteinuria].
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Dose-Response Relationship, Drug; Enalapril; Glom | 2000 |
[Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atenolol; Como | 2000 |
13 trials available for atenolol and Proteinuria
| Article | Year |
|---|---|
Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; Disease Progression; Enalapril | 2008 |
Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension.
Topics: Adult; Atenolol; Bed Rest; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1983 |
Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients.
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; Diabetic Neph | 1993 |
Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.
Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephrop | 1994 |
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Topics: Acebutolol; Adolescent; Adult; Aged; Atenolol; Blood Pressure; Body Weight; Enalapril; Female; Human | 1994 |
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 1996 |
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 1997 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 1999 |
Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2001 |
Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Chronic Disease; Diabetic Nephropathies; Diabetic Retinopa | 1991 |
Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; Hemodynamics; Humans; Kidne | 1991 |
The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment.
Topics: Adult; Atenolol; Bendroflumethiazide; Birth Weight; Drug Therapy, Combination; Embryonic and Fetal D | 1991 |
5 other studies available for atenolol and Proteinuria
| Article | Year |
|---|---|
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
[Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol].
Topics: Adolescent; Adult; Atenolol; Delivery, Obstetric; Ethanolamines; Female; Fetal Heart; Fetal Monitori | 1983 |
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Apolipoproteins; Atenolol; Biomarkers; Complement | 2000 |
Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome.
Topics: Adult; Atenolol; Body Weight; Captopril; Creatinine; Female; Furosemide; Humans; Hypertension; Lupus | 1990 |